Categories: BioTechDevelopment
Biopharmaceutical company developing therapeutics for orphan genetic diseases with a focus on neuromuscular disorders
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.07.2013 | IPO | $78M | - |
Mentions in press and media 3
| Date | Title | Description |
| 14.04.2015 | Duchenne Muscular Dystrophy market to shoot up 100-fold in five years | “These mutation-specific drugs are expected to have a high price point due to their novelty, efficacy and orphan drug status, and will contribute 85.6% to the DMD treatment arena by 2019,” GlobalData analyst Nikhilesh Sanyal said in a state... |
| 02.07.2013 | VC-backed Prosensa raises $78m in IPO | Dutch biotechnology company Prosensa Holding, which is backed by a consortium of venture capital firms, has listed on the Nasdaq Global Select Market in an IPO valuing the business at $408m. The company's venture capital backers - Idinvest ... |
| - | Duchenne Muscular Dystrophy market to shoot up 100-fold in five years | As a whole host of new Duchenne Muscular Dystrophy therapies mature down the regulatory pathway, the global market for the degenerative disease is expected to expand at an incredible rate – from $8.2 million in 2014 to $990 million in 2019,... |
Reviews 0
